AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22417085
Drug: Reduced individualized
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced individualized GH dose (RID, n=28)
Trial: 22417085
Drug: Unchanged individualized
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unchanged individualized GH dose (UID, n=37)
Trial: 22417085
Drug: Standard GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard GH dose (FIX, n=33)
Trial: 9266623
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (oral iron + r‐HuEPO)
Trial: 8278067
Drug: Meclofenamic acid
RxNorm normalized name: Meclofenamic Acid
DrugBank: Meclofenamic acid (DB00939)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meclofenamic acid 100 mg
Trial: 8278067
Drug: Ketoprofene 50
RxNorm normalized name: ketoprofen 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofene 50 mg
Trial: 15747895
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy intervention (EG-IA) - tooth brushing taught and monitored by an occupational therapist
Trial: 15747895
Drug: Placebo activity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo activity (CG-IA) - weekly manicure by the same person
Trial: 15747895
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy intervention (EG)
Trial: 2079571
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b 3 million units thrice weekly for 14-16 weeks
Trial: 37874
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of beta-blockers and diuretics
Trial: 31082269
Drug: NAB-paclitaxel 150
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NAB-paclitaxel 150 mg/m2 (after study amendment, 125 mg/m2)
Trial: 31082269
Drug: sb-paclitaxel 80
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: sb-paclitaxel 80 mg/m2
Trial: 31082269
Drug: NAB-paclitaxel 125
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NAB-paclitaxel 125 mg/m2
Trial: 31082269
Drug: NAB-paclitaxel 150
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NAB-paclitaxel 150 mg/m2
Trial: 26109117
Drug: Control cream
RxNorm normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control cream (Cetomacrogol)
Trial: 21550957
Drug: SimpleSTEP (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SimpleSTEP (insulin aspart added to the largest meal, titration based on premeal glucose values)
Trial: 21550957
Drug: ExtraSTEP (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ExtraSTEP (insulin aspart added to the meal with the largest prandial glucose increment, titration based on postmeal glucose values)
Trial: 17928808
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron supplementation (120 mg elemental iron)
Trial: 17928808
Drug: Weekly vitamin
RxNorm normalized name: Ezy Dose Weekly Vitamin Planner 2XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly vitamin A supplementation (25,000 IU)
Trial: 17095339
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) hydrofluoroalkane 88 mug, twice daily
Trial: 9507512
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (30 mg dose)
Trial: 2680497
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Milrinone + Digoxin)
Trial: 2680497
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment (3 months)
Trial: 1105178
Drug: Live, attenuated
RxNorm normalized name: Ebola Zaire vaccine (live, attenuated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live, attenuated intranasal influenza A vaccine
Trial: 27856633
Drug: PARI (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARI (2 μg/d) with regular sodium diet
Trial: 22744545
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment using the Cotrel-Dubousset method, assessed preoperatively and 12 months postoperatively.
Trial: 8542325
Drug: Melatonin (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (0.05 mg, 0.5 mg or 5 mg)
Trial: 7070696
Drug: Metoprolol (270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (270 mg/die per os)
Trial: 7070696
Drug: Labetalol (270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (270 mg/die per os)
Trial: 31451207
Drug: Budesonide-formoterol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide-formoterol (200 μg-6 μg Turbuhaler, one inhalation as needed)
Trial: 31451207
Drug: Maintenance budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Maintenance budesonide (200 μg Turbuhaler, one inhalation twice daily) plus terbutaline (250 μg Turbuhaler, two inhalations as needed)
Trial: 28114551
Drug: Tapering off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering off asthma medications over 4 study visits
Trial: 26460886
Drug: Higher-dose edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose edoxaban (HDE, 60 mg/30 mg)
Trial: 26460886
Drug: Lower-dose edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose edoxaban (LDE, 30 mg/15 mg)
Trial: 25632577
Drug: Mild moxibustion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild moxibustion of Neixiyan (EX-HE4) and Waixiyan (ST 35) for 30 min, once daily for 14 days, followed by moxibustion of Yaoyangguan (GV 3) and Mingmen (GV 4) once daily for next 7 days.
Trial: 25632577
Drug: Mild moxibustion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild moxibustion of Neixiyan (EX-HE4) and Waixiyan (ST 35) for 30 min, once daily for 14 days (control group).
Trial: 19546252
Drug: Cyclophosphamide (CYC)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CYC) 0.75 to 1.3 g as a 2‐hour infusion
Trial: 19546252
Drug: Midazolam 1
RxNorm normalized name: midazolam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 1 mg intravenous
Trial: 16796640
Drug: Pilocarpine gel
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine gel 4%
Trial: 1622739
Drug: Intrasplenic arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrasplenic arterial infusion of interleukin-2 (IS-IL-2)
Trial: 30962251
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid injection (ESI) in individuals with low non-immune-mediated HR (n=61)
Trial: 30962251
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid injection (ESI) in individuals with intermediate non-immune-mediated HR (n=52)
Trial: 30962251
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid injection (ESI) in individuals with high non-immune-mediated HR (n=24)
Trial: 30962251
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid injection (ESI) in individuals with low immune-mediated HR
Trial: 30962251
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid injection (ESI) in individuals with intermediate immune-mediated HR
Trial: 30962251
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid injection (ESI) in individuals with high immune-mediated HR
Trial: 28528859
Drug: Oral Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Cyclosporine A (CyA) at 3 mg/kg divided twice daily for 3 months
Trial: 23458037
Drug: Sevoflurane (2%)
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane (2%) and tramadol (2 mg/kg) combination
Trial: 18424221
Drug: Dopaminergic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopaminergic treatment in patients with PD
Trial: 18424221
Drug: Drug-naïve patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-naïve patients with PD
Trial: 3329532
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg terbutaline by metered dose inhaler (MDI)
Trial: 3329532
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg terbutaline subcutaneously (SC)
Trial: 3329532
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo SC plus 2 mg terbutaline by MDI
Trial: 3329532
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg terbutaline SC plus placebo by MDI
Trial: 11994056
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam (5 mg)
Trial: 11994056
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (5 mg)
Trial: 14676756
Drug: 2 grams
RxNorm normalized name: phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 grams of pheneticillin administered orally one hour before surgery
Trial: 14676756
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally one hour before surgery
Trial: 8864962
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pravastatin and sitostanol ester margarine
Trial: 8864962
Drug: Control margarine
RxNorm normalized name: MARGARINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control margarine (24 g daily)
Trial: 6084139
Drug: Guanabenz (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanabenz (average daily dosage 16 to 31 mg)
Trial: 6084139
Drug: Hydrochlorothiazide (HCTZ,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ, average daily dosage 50 to 75 mg)
Trial: 30001202
Drug: Adjuvant low-level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant low-level laser therapy
Trial: 30001202
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (topical medication and compressive therapy)
Trial: 27300579
Drug: Vildagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (50 mg twice daily = 100 mg/d)
Trial: 27300579
Drug: Sitagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (100 mg once daily for diet, 50 mg twice daily for metformin = 100 mg/d)
Trial: 16138073
Drug: Amicar (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amicar (100 mg/kg over 15 minutes, maintenance 10 mg/kg per hour until wound closure)
Trial: 7540965
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one matching tablet per day)
Trial: 1975851
Drug: Budesonide pressurised
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide pressurised aerosol 400 micrograms twice daily
Trial: 762813
Drug: Reserpine (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reserpine (0.125 to 0.250 mg) plus Hydroflumethiazide (50 or 100 mg)
Trial: 762813
Drug: Methyldopa (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (500 to 2,000 mg) plus Hydroflumethiazide (50 or 100 mg)
Trial: 762813
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 to 320 mg) plus Hydroflumethiazide (50 or 100 mg)
Trial: 29796932
Drug: Low-phytate wholegrain
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-phytate wholegrain bread (200 g/day)
Trial: 29796932
Drug: High-phytate wholegrain
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-phytate wholegrain bread (200 g/day)
Trial: 23986780
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi plus antihypertensive drugs
Trial: 21845243
Drug: MCBS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCBS with recombinant human platelet‐derived growth factor BB [rhPDGF‐BB; 0.3 mg/mL]
Trial: 21845243
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EMD with bone ceramic
Trial: 18663294
Drug: DPOAE Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPOAE Protocol P1 (L(1) = 60, L(2) = 50 dB SPL)
Trial: 18663294
Drug: DPOAE Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPOAE Protocol P2 (L(1) = 65, L(2) = 55 dB SPL)
Trial: 18663294
Drug: DPOAE Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPOAE Protocol P3 (L(1) = 75, L(2) = 65 dB SPL)
Trial: 14681716
Drug: hyperosmolality induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperosmolality induced by fluid restriction and intravenous infusion of hypertonic NaCl (2‐5%, wt/vol) during 17 h
Trial: 14681716
Drug: hypo‐osmolality produced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hypo‐osmolality produced by intravenous administration of desmopressin, liberal water drinking and infusion of hypotonic saline (0.4%)
Trial: 14681716
Drug: iso‐osmolality study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iso‐osmolality study with oral water intake ad libitum
Trial: 9089663
Drug: Botulinum neurotoxin
RxNorm normalized name: Botulinum neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin type A (BoNt/A) preparation 1 injected into the left foot
Trial: 9089663
Drug: Botulinum neurotoxin
RxNorm normalized name: Botulinum neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin type A (BoNt/A) preparation 2 injected into the right foot
Trial: 9089663
Drug: Both preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both preparations (1 and 2)
Trial: 7933838
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human IGF-I (rhIGF-I) (100 micrograms/kg body wt subcutaneously twice daily) - short-term treatment (4 days)
Trial: 7933838
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human IGF-I (rhIGF-I) (100 micrograms/kg body wt subcutaneously twice daily) - long-term treatment (13-27 days)
Trial: 3220789
Drug: Single volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single volume exchange transfusion (ET; 80 ml/kg)
Trial: 3220789
Drug: Double volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double volume exchange transfusion (ET; 160 ml/kg)
Trial: 1985161
Drug: Long arm
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long arm (5 additional courses with 2 additional drugs; 16 weeks)
Trial: 9665188
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment arms (short and long)
Trial: 872103
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy and/or immunotherapy
Trial: 29065916
Drug: Sertraline starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline starting at 50 mg daily for 1 week, increasing to 100 mg daily for up to 11 weeks (with the option of increasing to 150 mg if required)
Trial: 24020866
Drug: Naloxone (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (3.2 mg/70 kg body weight)
Trial: 19701110
Drug: Pemetrexed at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed at 750 mg/m2 every 21 days with weekly cetuximab at 250 mg/m2
Trial: 19701110
Drug: Historical controls
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical controls of either single agent
Trial: 18000101
Drug: Significant other
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Significant other primes (e.g., mother, roommate)
Trial: 12849651
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa inhibitors with thrombolytic agents
Trial: 12849651
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with GP IIb/IIIa inhibitors and thrombolytic agents
Trial: 12119202
Drug: Atorvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (40 mg per day)
Trial: 21473764
Drug: Inhaled beclometasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclometasone (400 μg per day) with atorvastatin
Trial: 10769276
Drug: Ciprofibrate therapy
RxNorm normalized name: ciprofibrate
DrugBank: Ciprofibrate (DB09064)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofibrate therapy
Trial: 9068936
Drug: Sertraline tablets
RxNorm normalized name: sertraline Oral Tablet
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline tablets (morning administration)
Trial: 9068936
Drug: Sertraline tablets
RxNorm normalized name: sertraline Oral Tablet
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline tablets (evening administration)
Trial: 9068936
Drug: Sertraline tablets
RxNorm normalized name: sertraline Oral Tablet
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline tablets (with food)
Trial: 9068936
Drug: Sertraline tablets
RxNorm normalized name: sertraline Oral Tablet
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline tablets (without food)
Trial: 25786565
Drug: SRP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP plus 1.2 mg rosuvastatin gel
Trial: 21703001
Drug: Patient education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient education integrated with acupuncture (two parts: self-care education in four weekly 50-minute sessions and eight weekly 50-minute acupuncture sessions)
Trial: 16875647
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methylprednisolone (100 mg every 4 hours)
Trial: 25667122
Drug: Rocuronium (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium (0.9 mg kg(‐1))
Trial: 21908961
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia (SA) with 3 ml of 0.75% ropivacaine
Trial: 21908961
Drug: Combined sciatic/lumbar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined sciatic/lumbar plexus nerve block (CSLPB) with 10 ml 0.75% ropivacaine and 10 ml of normal saline (20 ml total)
Trial: 14622081
Drug: Fluoxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine plus self-exposure (FLU + SE)
Trial: 7588456
Drug: Patients receiving
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving long-term anticonvulsant therapy
Trial: 2121394
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (buserelin) 100 micrograms
Trial: 582772
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg WE 941
Trial: 582772
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg WE 941